Current stage-Stage III Posts on Medivizor
Navigation Menu

Current stage-Stage III Posts on Medivizor

Investigating the benefit of frequent surveillance imaging on the survival outcomes in patients with resected stage III melanoma.

Investigating the benefit of frequent surveillance imaging on the survival outcomes in patients with resected stage III melanoma.

Posted by on May 8, 2022 in Melanoma | 0 comments

In a nutshell This study investigated the benefit of frequent surveillance imaging on the survival outcomes in patients with resected stage III melanoma. The data showed that patients who underwent less frequent imaging (12-monthly) had better outcomes than those who underwent more frequent imaging (3- to 4-monthly). Some background Melanoma is a...

Read More

Comparing the effectiveness of immune-based combination therapies as first-line treatment for advanced non-small cell lung cancer.

Comparing the effectiveness of immune-based combination therapies as first-line treatment for advanced non-small cell lung cancer.

Posted by on Dec 31, 2021 in Lung cancer | 0 comments

In a nutshell This study compared the effectiveness of immune-based combination therapies as first-line treatment for advanced non-small-cell lung cancer (NSCLC). The data showed that immunotherapies plus chemotherapy combination was the best treatment for improving overall survival whereas, immunotherapy plus anti-angiogenic therapy plus chemotherapy...

Read More

Investigating the side effect profiles of different PD-L1/PD-1 inhibitor-based combination therapies.

Investigating the side effect profiles of different PD-L1/PD-1 inhibitor-based combination therapies.

Posted by on Nov 7, 2021 in Lung cancer | 0 comments

In a nutshell This study investigated the side effect profiles of different PD-1/PD-L1 inhibitor-based combination therapies. The data showed that PD-1/PD-L1 inhibitors in combination with chemotherapy were associated with a higher risk of treatment-related side effects than with targeted therapy or immunotherapy combinations. Some background...

Read More

Do tyrosine kinase inhibitors benefit patients with mutant inoperable NSCLC?

Do tyrosine kinase inhibitors benefit patients with mutant inoperable NSCLC?

Posted by on Sep 16, 2021 in Lung cancer | 0 comments

In a nutshell This study evaluated whether patients with unresectable non-small-cell lung cancer (NSCLC) having genetic mutations could benefit from first-line treatment with tyrosine kinase inhibitor (TKI) therapy. The data showed that TKIs could be a good option for these patients. Some background NSCLC is the most common form of lung cancer....

Read More

Long-term outcomes of pembrolizumab therapy for patients with stage III melanoma removed surgically

Long-term outcomes of pembrolizumab therapy for patients with stage III melanoma removed surgically

Posted by on May 16, 2021 in Melanoma | 0 comments

In a nutshell The aim of this study was to investigate the long-term safety and effectiveness of pembrolizumab (Keytruda) for patients with stage III melanoma that was surgically removed. The study found that patients treated with pembrolizumab were more likely to have an improved outcome.   Some background Melanoma is one of the most...

Read More

Comparing the long-term effectiveness of integrated IMRT vs segmented 3D-CRT after modified breast removal surgery in breast cancer patients

Comparing the long-term effectiveness of integrated IMRT vs segmented 3D-CRT after modified breast removal surgery in breast cancer patients

Posted by on Apr 3, 2021 in Breast cancer | 0 comments

In a nutshell This study compared the long-term effectiveness of integrated intensity-modulated radiation therapy (IMRT) and segmented 3D-conventional radiotherapy (3D-CRT) following breast-removal surgery (radical mastectomy) in patients with breast cancer (BC). The data showed that integrated IMRT reduced the recurrence rate in the long-term with...

Read More

Looking for patients with HER-2 positive advanced breast cancer to trial an experimental treatment.

Looking for patients with HER-2 positive advanced breast cancer to trial an experimental treatment.

Posted by on Jan 28, 2021 in Breast cancer | 0 comments

In a nutshell This trial is aiming to examine the safety and effectiveness of an experimental treatment called BPX-063, a CAR-T cell treatment, in patients with advanced HER-2 positive breast cancer. The main outcomes to be measured are the maximum tolerated dose of BPX-603 and the antitumor activity. This trial is being carried out across the...

Read More

Irinotecan combined with capecitabine-based chemoradiotherapy before surgery improves the outcomes of patients with rectal cancer

Irinotecan combined with capecitabine-based chemoradiotherapy before surgery improves the outcomes of patients with rectal cancer

Posted by on Nov 29, 2020 in Colorectal cancer | 0 comments

In a nutshell This study investigated the effectiveness of treatment with irinotecan (Camptosar) combined with capecitabine (Xeloda) chemotherapy (ICC) before rectal cancer surgery. Researchers suggested that this combined therapy significantly improved the treatment outcomes in these patients. Some background Rectal cancer is a common...

Read More

Searching for patients with non-small cell lung cancer to trial an immune treatment

Searching for patients with non-small cell lung cancer to trial an immune treatment

Posted by on Nov 22, 2020 in Lung cancer | 0 comments

In a nutshell This trial is being carried out to examine the effectiveness of a new immune therapy, zimberelimab, alone or in combination with other immune therapies (domvanalimab and etrumadenant) in patients with PD-L1 positive non-small cell lung cancer (NSCLC). The main outcomes to be measured in this trial is the response rate and survival...

Read More

Investigating the effectiveness of the treatment combination atezolizumab with chemotherapy before surgery for early triple negative breast cancer

Investigating the effectiveness of the treatment combination atezolizumab with chemotherapy before surgery for early triple negative breast cancer

Posted by on Oct 11, 2020 in Breast cancer | 0 comments

In a nutshell This study investigated the effectiveness and safety of atezolizumab (Tecentriq) as an addition to chemotherapy before surgery for patients with early-stage triple-negative breast cancer (TNBC). The data showed that the combination is effective in improving treatment response in these patients. Some background...

Read More

Searching for patients with advanced triple-negative breast cancer to trial a treatment combination

Searching for patients with advanced triple-negative breast cancer to trial a treatment combination

Posted by on Sep 6, 2020 in Breast cancer | 0 comments

In a nutshell This trial is aiming to examine the effectiveness of ipatasertib in combination with atezolizumab (Tecentriq) and paclitaxel (Taxol) for the treatment of advanced triple-negative breast cancer (TNBC) that cannot be surgically removed. The main outcomes to be measured in this trial is survival without progression of the disease and...

Read More